Among BCG-vaccinated children having a BCG scar was associated with lower mortality: 52% (10-74%) during the first year of life and 26% (4-44%) during the first 5 years. Scar-positive children were also less likely to be admitted to hospital. 
INTRODUCTION
Bacillus Calmette-Guerin (BCG) vaccine is recommended at birth in low income countries to induce immunity against tuberculosis (TB). At present about 100 million children receive BCG vaccine each year [1] . Intradermal BCG vaccination is normally followed by development of a papule which ulcerates and heals spontaneously leaving a permanent scar within a few months [1] .
Several observational studies from Guinea-Bissau in West Africa [2] [3] [4] [5] and elsewhere [6] [7] [8] [9] have suggested that the BCG vaccine has strong positive effects beyond protecting against TB. Randomised trials among low birth-weight children (<2500 g), for whom BCG is normally delayed, have shown that early BCG vaccination reduces neonatal mortality by 48% [10, 11] . In a randomised trial of BCG revaccination, child mortality was reduced by 64% when BCG was given to 19-month-old children who had received booster DTP [12] . TB does not cause 48-64% of early childhood deaths [13] and thus these strong beneficial effects cannot be ascribed to protection against TB. The reduction in neonatal mortality was due to fewer cases of sepsis and respiratory infections among the BCG-vaccinated neonates [10, 11] . Recent immunological studies have shown that BCG induces epigenetic modulations in monocytes and increased responsiveness against unrelated stimuli, thus providing a plausible immunological mechanism behind the beneficial non-specific effects [14, 15] .
Prospective studies from urban Guinea-Bissau have demonstrated a survival advantage during the first 1-1.5 years of life among those who developed a scar versus those who did not develop a scar after BCG vaccination [3, 5, 16] . This was unlikely to be due to resistance to TB since exclusion of children exposed to TB at home did not change the association [3, 5, 16] . Not all BCG-vaccinated children develop a BCG scar. In studies from urban Guinea-Bissau the prevalence was 72-97% [3, 5, 16, 17] which is similar to the scar prevalence found in other sub-Saharan studies [18] [19] [20] .
Correct vaccination technique is important for scar development [1, 21] and differences in vaccination technique may explain some of the observed variations. However, studies have also suggested that different BCG strains have different capacity to generate a scar [5, 22] .
In the present study we examined the association between BCG scar and overall mortality and hospital admissions among BCG-vaccinated children in rural Guinea-Bissau. We hypothesised that those having a BCG scar had lower at Statens Serum Institute on June 18, 2015 http://cid.oxfordjournals.org/
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METHODS

Setting and study population
The study was conducted in Guinea-Bissau, where children receive BCG at government health centres and hospitals throughout the country. The Bandim Health Project's Health and Demographic Surveillance System (HDSS) follows 182 randomly selected clusters of 100 women of fertile age and their children in rural Guinea-Bissau. Children are followed from first registration until migration, death or 5 years of age (Supplementary Material). At all visits vaccination status is assessed by inspection of the vaccination card and the child's upper-arm is inspected for a BCG scar. If a scar is found, two perpendicular diameters are measured. It is noted which fieldworker read the scar.
The study population for the present study was extracted from the HDSS cohort. All BCG-vaccinated children less than 5 years of age visited between 01 July 2009 and 30 June 2011 were eligible for the study if they had been present for inspection of their arm for a scar. Children without a documented BCG vaccination or vaccinated less than 31 days prior to scar reading were excluded from the analysis (Supplementary Material).
Statistical methods
First, we compared background variables between scar-positive and scar-negative children using data from the first visit with a scar reading (Supplementary Material).
Second, in a Cox proportional hazards model with age as underlying time we compared mortality and hospital admission rates among scar-positive and scar-negative children. The analyses followed children from the visit where scar status was assessed during the subsequent 6 months or to the next visit, migration, death, or hospital admission (Supplementary material). We adjusted the 95% confidence interval (CI) for village cluster using robust variance estimates. We report the estimates for the entire population and stratified by sex and age (Supplementary material).
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To assess a possible impact of scar size on mortality, we defined scar size as the average of the horizontal and vertical diameter. Children were divided into three groups: no scar, below and above the median. Mortality rates in the three groups were compared in the Cox-model. Previous studies have found lower mortality among children vaccinated early [3, 23] . We investigated whether the association between scar positivity and mortality varied by age of BCG vaccination (1   st   , 2 nd -4 th , >4 th week).
All background variables were included one by one in the Cox proportional hazards model to see how much each variable changed the unadjusted mortality rate ratio (MRR). The estimate was compared with an unadjusted estimate for the same records. Any variable changing the MRR by 10% or more would be included in the Cox proportional hazard model to obtain adjusted MRRs for scar-positive versus scar-negative children. The robustness of the results was tested in sensitivity analyses (Supplementary material). Data were analysed using Stata 11.2 (StataCorp, College Station, TX).
All tests were 2-sided. 
RESULTS
Between
Determinants for scar development
Among BCG-vaccinated children, several background variables were associated with having a BCG scar: Scar prevalence was lower among girls, the relative risk (RR) for girls compared with boys being 0.96 (0.93-0.99). Scar prevalence was higher in the rainy than the dry season (RR=1.05 (1.01-1.09)). Scar prevalence also varied by sequence of vaccinations, place of birth, health region, fieldworker who conducted the scar reading, and maternal ethnicity but did not depend on the nutritional status of the child or the mother (Table 1) . When the analysis was stratified by age at vaccination, the stratum specific estimates were not homogenous. (Table 3) . Hence, the association was significantly modified by age at vaccination (p=0.01 for interaction between scar status and age at vaccination on mortality). No sex-difference was seen in either of the vaccination age groups (p=0.88, p=0.97 and p=0.57 for interaction between scar status and sex on mortality in each age group, respectively).
All background variables were tested for their ability to change the MRR; none of the variables changed the estimate by more than 1.2% and no adjusted analysis was made.
Cause of death
Based on interviews conducted following the deaths, fever without other reported symptoms was reported as the cause for 60% (145/243) of the deaths. Diarrhoea was the major symptom in 25% (61/243) and cough or difficulties breathing was the major symptom in 12% (28/243) (Supplementary Table 2 ). The association between scar positivity and mortality differed significantly by cause of death: The association was particularly strong with respect to respiratory symptoms (MRR=0.20 (0.07-0.55)) whereas associations were weaker for fever (MRR=0.81 (0.57-1.16)) and diarrhoea (MRR=0.88 (0.53-1.45)) (p=0.04 for same effect) (Supplementary Table 2) . A c c e p t e d M a n u s c r i p t
Admission to hospital
In this rural area hospitalisations were rare, the overall admission rate being 14/1000 person years of observation. There were 99 hospital admissions among scar-positive children and 125 among scar-negative children ( Figure 1 ). Compared with children without a scar, children with a BCG scar had a lower overall hospital admission rate, the incidence rate ratio (IRR) being 0.74 (0.60-0.92) ( Table 4) (Table 4) .
Sensitivity analyses
Some fieldworkers classified fewer or more children as scar-positive (Table 1, Supplementary Table 3 ). Excluding children with readings done by fieldworkers >=15% from the median or stratifying by fieldworker had no effect on the 
DISCUSSION
Main results
Only approximately half of the children developed a BCG scar. Among BCG-vaccinated individuals, children with a BCG scar had a lower overall mortality rate compared with children without a scar. The effect was strongest for children vaccinated within the first month of life. Infant mortality for scar-positive children was half the mortality for scar-negative children. The mortality difference between scar-negative and scar-positive children diminished but was still present during the second and third-fifth year of life. Scar-positive children were also less likely to be admitted to hospital.
Strengths and weaknesses
This study was based on a country-representative population; all regions outside the capital, Bissau being represented.
The surveyed households have been routinely visited for years and the fieldworkers were experienced and frequently A c c e p t e d M a n u s c r i p t 8 supervised during the study period. A source of bias is the accuracy with which scar status has been classified. Due to the prospective study design the outcome was unknown when scar status was assessed and the fieldworkers were not aware of the hypothesis. Exclusion of readings by the most extreme scar-reading fieldworkers, or stratifying the analysis by fieldworker, did not alter the conclusions. The fieldworkers are trained to use local expressions to explain symptoms to the respondent in the verbal autopsy interview. However, the symptom data are crude and should be interpreted cautiously; while the results did suggest that a BCG scar is particularly associated with fewer deaths from respiratory infections these deaths were only a small proportion of all deaths.
Consistency with previous studies
We found remarkably lower scar prevalence in the rural Guinean cohort (52%) than has been found previously in the urban Guinean cohorts (72-97%) [3, 5, 16, 17] . A possible explanation is that the vaccine strain used in rural Guinea- Three prospective studies in urban Guinea-Bissau have previously shown that among BCG-vaccinated children, scar positivity was associated with reduced childhood mortality [3, 5, 16] . This study corroborated these findings in a large cohort from a rural setting with much lower scar prevalence and notably also with less than half the infant mortality seen in the previous studies. Two of the previous studies compared mortality until the age of 1 year, the adjusted MRR being 0.45 (0.21-0.96) [16] and 0.44 (0.23-0.81) [5] , very similar to what we found during first year of life (MRR=0.48
(0.26-0.90) [3, 5, 16] . Also consistent with the previous studies [3, 5, 16] , the association between scar positivity and lower mortality weakened with age but was still present during the second year of life. In contrast to the beneficial nonspecific effects of a scar among BCG-vaccinated children, a large study from Malawi did not find that having a BCG scar protected against TB in the general population [24] .
Only one of the previous studies has examined the influence of having a scar on different causes of death and found no difference for cause of death [16] . However, in case-control studies from Guinea-Bissau and Brazil, BCG vaccination A c c e p t e d M a n u s c r i p t 9 was associated with reduced risk of lower respiratory tract infections [25, 26] . Furthermore, a recent paper describes that being BCG-vaccinated was associated with a lower prevalence of respiratory symptoms in the past 14 days [6] .
Interpretation
Immunological studies have shown that BCG vaccination induces epigenetic modifications of monocytes, resulting in increased pro-inflammatory monocyte-derived cytokine response when subsequently exposed to unrelated bacterial and fungal pathogens [14, 27] . This phenomenon may provide an explanation for the non-specific effects of BCG. The present study suggests that the non-specific effects of BCG are more pronounced among children who develop a scar, and thus the scar can be seen as a sign of a generally enhanced resistance towards pathogens.
We assessed several underlying factors related to the child and mother for their association with both scar and mortality to identify possible confounders, but none of these factors could explain the association between scar positivity and lower mortality. It could be speculated that the association between scar and mortality might reflect host immune characteristics prior to BCG vaccination, i.e. neonates with impaired or immature immune system may fail to form a scar after BCG vaccination and also fail to fight infection, a "healthy reactor effect". HIV-infection is associated with both immune competence and mortality, and children of HIV-infected mothers were therefore excluded in another scar study [3] , but it had no impact on the estimate. The HIV prevalence among pregnant women in Guinea-Bissau was 5.8 % in 2009[28], thus HIV alone cannot explain that almost half of the children in our study were scar-negative. Pre-term and low birth-weight infants have been less likely to develop a scar[21, 29, 30], but again this cannot explain the high rate of scar negativity in the present study. Also, we did not see lower scar prevalence among twins, who are often preterm and/or small for gestational age. We assessed whether children with poor nutritional status (measured by MUACfor-age) and whether children of mothers with poor nutritional status were less likely to develop a scar, but they were not. First and foremost, it would be unlikely that we found the scar prevalence so much lower than other studies from Guinea-Bissau if scar reaction is determined by an underlying biological factor. Hence, we do not believe our results A c c e p t e d M a n u s c r i p t 10 present study may therefore partially be due to the use of a BCG stain that causes fewer scars. Furthermore, poor vaccination technique may contribute to explain the low scar prevalence, as staff is less experienced in the rural areas of Guinea-Bissau where 1-2 nurses handle all tasks at a health centre, whereas at the larger health facilities in the capital BCG vaccination is delegated to specialized nurses.
Implications
Vaccines are considered one of the most successful and cost-effective health investments in history [31] . However, our study indicates that we may not obtain the maximum benefit of BCG vaccination. Improving and sustaining successful health interventions rely on continued monitoring, evaluation and redesigning of evaluation criteria to ensure that the most important parameters are assessed. At present the programme performance with regards to BCG vaccinations is assessed by measuring BCG coverage at 12 months of age. Currently programme strategy does not encourage early delivery of BCG and less than half of the children are vaccinated in the first month of life [32, 33] .
The present analysis identified several potential problems in the current BCG vaccination programme which could lead to considerably lower mortality if resolved. First, BCG is more beneficial the earlier it is given, but this is not taken into consideration in the current program. Second, there is a need to monitor the quality of vaccination technique and to which extent a BCG scar is developed. Third, strain of BCG may be a determinant of BCG scarring. Since scarring is related to mortality risk, the strain of BCG used may have a major impact on the mortality level. There would seem to be a need to conduct randomized trials of different strains of BCG to identify those most effective in providing beneficial non-specific effects and to test whether revaccination with BCG will improve the survival of scar-negative children.
Conclusion
BCG scar was a marker of reduced mortality and reduced risk of hospital admission. Such effects should be taken into account in the planning of vaccination programmes. Much could be gained by using BCG scar prevalence and age of BCG vaccination as programme performance indicators rather than merely assessing BCG coverage by 12 month of age. Further studies are required to investigate whether revaccination of scar-negative children should be recommended. A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 
